Q-omics provides the consensus-scored SYNDIG1L profile across patient tissues and cancer cell-line models. SYNDIG1L expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SYNDIG1L is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, SYNDIG1L RNA expression shows 12,205 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, LUAD, and TGCT as cancer lineages where SYNDIG1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYNDIG1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYNDIG1L survival associations across molecular data types. SYNDIG1L RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYNDIG1L RNA expression–survival associations across cancer types. High SYNDIG1L expression shows unfavorable associations in BLCA and COAD, but favorable associations in SKCM, CESC, THCA and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SYNDIG1L RNA expression.
This table summarizes SYNDIG1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for SYNDIG1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYNDIG1L shows lower tumor expression in LUAD, LUSC, READ, COAD and BRCA and higher tumor expression in THCA. The LUAD box plot shows higher SYNDIG1L RNA expression in normal versus tumor tissue (log2 FC = −2.310, t-test p < 0.001).
This table shows molecular features associated with SYNDIG1L in patient tissues and cancer cell lines. In patient samples, SYNDIG1L shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SYNDIG1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
